Glyxambi ema approval date?

What was the EMA approval date for Glyxambi?

Glyxambi (empagliflozin/linagliptin) received European Medicines Agency (EMA) approval on 22 August 2014. [1]

What product did the EMA approve under Glyxambi?

The EMA authorization was for Glyxambi, a fixed-dose combination of empagliflozin and linagliptin for use in type 2 diabetes mellitus. [1]

Is there an EMA “approval date” vs. launch date?

Yes. The EMA date refers to the marketing authorization approval date by the agency (22 August 2014 for Glyxambi), which is different from when the product became available in specific EU/EEA markets. [1]

Sources

[1] https://www.ema.europa.eu/en/medicines/human/EPAR/glyxambi